ReFacto AF
Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
Ulotka dla pacjenta
(PIL)
08-11-2022
Charakterystyka produktu
(SPC)
08-11-2022
Sprawozdanie z oceny publicznego
(PAR)
29-09-2016
Składnik aktywny:
moroctocog alfa
Dostępny od:
Pfizer Europe MA EEIG
Kod ATC:
B02BD02
INN (International Nazwa):
moroctocog alfa
Grupa terapeutyczna:
Antihemorrhagics
Dziedzina terapeutyczna:
Hemophilia A
Wskazania:
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). ReFacto AF is appropriate for use in adults and children of all ages, including newborns. ReFacto AF does not contain von-Willebrand factor, and hence is not indicated in von-Willebrand's disease.,
Podsumowanie produktu:
Revision: 40
Status autoryzacji:
Authorised
Data autoryzacji:
1999-04-13
Ulotka dla pacjenta
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ReFacto AF 250 IU powder and solvent for solution for injection
ReFacto AF 500 IU powder and solvent for solution for injection
ReFacto AF 1000 IU powder and solvent for solution for injection
ReFacto AF 2000 IU powder and solvent for solution for injection
ReFacto AF 250 IU powder and solvent for solution for injection in
pre-filled syringe
ReFacto AF 500 IU powder and solvent for solution for injection in
pre-filled syringe
ReFacto AF 1000 IU powder and solvent for solution for injection in
pre-filled syringe
ReFacto AF 2000 IU powder and solvent for solution for injection in
pre-filled syringe
ReFacto AF 3000 IU powder and solvent for solution for injection in
pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ReFacto AF 250 IU powder and solvent for solution for injection
Each vial contains nominally 250 IU* moroctocog alfa**.
After reconstitution, each mL of solution contains approximately 62.5
IU moroctocog alfa.
ReFacto AF 500 IU powder and solvent for solution for injection
Each vial contains nominally 500 IU* moroctocog alfa**.
After reconstitution, each mL of solution contains approximately 125
IU moroctocog alfa.
ReFacto AF 1000 IU powder and solvent for solution for injection
Each vial contains nominally 1000 IU* moroctocog alfa**.
After reconstitution, each mL of solution contains approximately 250
IU moroctocog alfa.
ReFacto AF 2000 IU powder and solvent for solution for injection
Each vial contains nominally 2000 IU* moroctocog alfa**.
After reconstitution, each mL of solution contains approximately 500
IU moroctocog alfa.
ReFacto AF 250 IU powder and solvent for solution for injection in
pre-filled syringe
Each pre-filled syringe contains nominally 250 IU* moroctocog alfa**.
After reconstitution, each mL of solution contains approximately 62.5
IU moroctocog alfa.
ReFacto AF 500 IU powder and solvent for solution for injection in
pre-filled syringe
Each pre-filled syringe contains nominally 500 IU* moroctoco
Przeczytaj cały dokument
Charakterystyka produktu
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ReFacto AF 250 IU powder and solvent for solution for injection
ReFacto AF 500 IU powder and solvent for solution for injection
ReFacto AF 1000 IU powder and solvent for solution for injection
ReFacto AF 2000 IU powder and solvent for solution for injection
ReFacto AF 250 IU powder and solvent for solution for injection in
pre-filled syringe
ReFacto AF 500 IU powder and solvent for solution for injection in
pre-filled syringe
ReFacto AF 1000 IU powder and solvent for solution for injection in
pre-filled syringe
ReFacto AF 2000 IU powder and solvent for solution for injection in
pre-filled syringe
ReFacto AF 3000 IU powder and solvent for solution for injection in
pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ReFacto AF 250 IU powder and solvent for solution for injection
Each vial contains nominally 250 IU* moroctocog alfa**.
After reconstitution, each mL of solution contains approximately 62.5
IU moroctocog alfa.
ReFacto AF 500 IU powder and solvent for solution for injection
Each vial contains nominally 500 IU* moroctocog alfa**.
After reconstitution, each mL of solution contains approximately 125
IU moroctocog alfa.
ReFacto AF 1000 IU powder and solvent for solution for injection
Each vial contains nominally 1000 IU* moroctocog alfa**.
After reconstitution, each mL of solution contains approximately 250
IU moroctocog alfa.
ReFacto AF 2000 IU powder and solvent for solution for injection
Each vial contains nominally 2000 IU* moroctocog alfa**.
After reconstitution, each mL of solution contains approximately 500
IU moroctocog alfa.
ReFacto AF 250 IU powder and solvent for solution for injection in
pre-filled syringe
Each pre-filled syringe contains nominally 250 IU* moroctocog alfa**.
After reconstitution, each mL of solution contains approximately 62.5
IU moroctocog alfa.
ReFacto AF 500 IU powder and solvent for solution for injection in
pre-filled syringe
Each pre-filled syringe contains nominally 500 IU* moroctoco
Przeczytaj cały dokument
